Comparison of the monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts
1996

Comparing Monoclonal Antibodies for Ovarian Cancer Treatment

Sample size: 7 publication Evidence: moderate

Author Information

Author(s): E Kievit, HM Pinedo, HMM Schliiper, HJ Haisma, E Boven

Primary Institution: Free University Hospital

Hypothesis

Does the affinity of monoclonal antibodies affect their tumor uptake and efficacy in radioimmunotherapy for ovarian cancer?

Conclusion

High-affinity monoclonal antibody m-323/A3 showed better tumor targeting but lower efficacy compared to low-affinity c-17-lA when radiation doses were adjusted for equivalent tumor uptake.

Supporting Evidence

  • High-affinity m-323/A3 had a 5-fold higher affinity than low-affinity c-17-lA.
  • m-323/A3 delivered 2.5- to 4.7-fold higher radiation doses to tumor tissue compared to c-17-lA.
  • c-17-lA was more effective in tumor growth inhibition when radiation doses were adjusted for equivalent uptake.

Takeaway

This study looked at two types of antibodies to see which one works better for treating cancer. One type sticks to the tumor better, but the other type helps stop the tumor from growing more.

Methodology

The study involved in vitro binding assays and in vivo experiments using nude mice with human ovarian cancer xenografts to compare the pharmacokinetics and therapeutic efficacy of two monoclonal antibodies.

Limitations

The study was conducted in a mouse model, which may not fully replicate human responses.

Participant Demographics

Female athymic nude mice were used in the experiments.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication